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Abstract Commercial probiotics preparation containing
Bacillus coagulans have been sold in the market for several
decades. Due to its high intra-species genomic diversity, it is
very likely that B. coagulans strain may alter in different
ways over multiple years of production. Therefore, the pre-
sent study focuses to evaluate the genetic consistency and
probiotic potential of B. coagulansMTCC 5856. Phenotypic
and genotypic techniques including biochemical profiling,
16S rRNA sequencing, GTG 500, BOX PCR fingerprinting,
and Multi-Locus-Sequence typing (MLST) were carried out
to evaluate the identity and consistency of the B. coagulans
MTCC 5856. Further, in vitro probiotic potential, safety and
stability at ambient temperature conditions of B. coagulans
MTCC 5856 were evaluated. All the samples were identified
as B. coagulans by biochemical profiling and 16S rRNA
sequencing. GTG 500, BOX PCR fingerprints and MLST
studies revealed that the same strainwas present over 3 years
of commercial production. B. coagulans MTCC 5856
showed resistance to gastric acid, bile salt and exhibited
antimicrobial activity in in-vitro studies. Additionally, B.
coagulans MTCC 5856 was found to be non-mutagenic,
non-cytotoxic, negative for enterotoxin genes and stable at
ambient temperature (25 ± 2 C) for 36 months. The data
of the study verified that the same strain of B. coagulans
MTCC 5856 was present in commercial preparation over
multiple years of production.
Keywords Bacillus coagulans MTCC 5856  16S rRNA 
MLST  Genotypic fingerprinting  LactoSpore
Introduction
The traditional use of probiotics in dairy products for human
consumption has a long history in several parts of the world.
As per FAO/WHO, probiotics are defined as ‘‘live microor-
ganisms which, when administered in adequate amounts,
confer a health benefit on the host’’ (FAO/WHO 2002). The
most commonly used bacterial genera in probiotic prepa-
rations are Lactobacillus, Bifidobacterium, Enterococcus,
Bacillus and Streptococcus. Some fungal strains belonging
to Saccharomyces have also been used. Probiotics have been
shown to be effective in varied clinical conditions—ranging
from infantile diarrhoea, necrotizing enterocolitis, antibi-
otic-associated diarrhoea, relapsing Clostridium difficile
colitis, Helicobacter pylori infections, inflammatory bowel
and female urogenital infection (Gill and Prasad 2008; Shida
and Nomoto 2013). There are number of probiotics strains
used in dietary supplements and foods worldwide. However,
the contents of commercial probiotics intended for both
human and animal use are often not accurately represented
on their labels. Several studies conducted independently
revealed that a large percentage of products did not contain
the specified organisms, contained other species of organ-
isms, or did not contain the stated numbers of organisms
(Hamilton-Miller and Shah 2002; Weese 2002; Hughes and
Hillier 1990; Gilliland et al. 1984; Canganella et al. 1997). A
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survey on probiotics sold in Italy revealed that many of the
commercial probiotic products do not comply with what
their labels claim and consequently with what the Italian
guidelines suggest. Notably, B. coagulanswas absent in 5 of
17 preparations that were presumed to contain B. coagulans
(‘‘L. sporogenes’’) according to the label, and also only in 8
of 17 preparations with B. coagulans the authors were able
to find living B. coagulans cells/spores (Aureli et al. 2010).
Hence, there is a need to identify the specified organism
claimed to be present in commercial probiotic preparations.
Bacillus coagulans is a very heterogeneous species with
a high intra-species genomic diversity (De Clerck et al.
2004). This was confirmed by Patel et al. (2006), who
isolated a number of thermophilic acid tolerant bacteria
most of which belonged to the species B. coagulans.
Notably, these authors also found that B. coagulans
apparently has several different type strains, meaning that
the ‘‘type strain’’ has a different 16S rRNA sequence when
ordered from different culture collections. B. coagulans
genome contains a very large number of insertion sequence
(IS) elements, which leads to major difficulties in assembly
of the sequence and to ‘‘reshuffling’’ of the genome during
growth/stress, potentially causing variability between dif-
ferent batches of production over a period of time.
Hence, it is essential to evaluate the phenotypic and
genotypic consistency of probiotic ingredients contain-
ing B. coagulans.
LactoSpore is a commercial probiotic preparation
which contains the spores of B. coagulans MTCC 5856
(earlier known as Lactobacillus sporogenes). Commercial
preparations of B. coagulans in powder, tablet and capsule
forms have been successfully used in several human studies
for the treatment of gastrointestinal disorders, vaginal
infections, hypercholesterolemia, lactose intolerance, hep-
atic coma and as an adjuvant to antibiotic therapy (Majeed
and Prakash 1998; Anonymous 2002; Jurenka 2012). The
primary aim of this study was to assess the genetic consis-
tency of B. coagulans MTCC 5856 strain over 3 years of
commercial production by biochemical profiling and
advanced molecular typing techniques. B. coagulansMTCC
5856 has been established safe and effective for human use
over the last two decades (Majeed and Prakash 1998).
However, it is essential to evaluate probiotic potential,
safety and stability of B. coagulans MTCC 5856 as these
properties may also be the indicators of genetic stability.
Materials and methods
Bacterial strains
The bacteria used in this study included Staphylococcus
aureus ATCC 29213, Staphylococcus epidermidis ATCC
14990, Streptococcus mutans MTCC 1943, Propionibac-
terium acnes ATCC 11827, Bacillus cereus ATCC 14579,
Pseudomonas aeruginosa ATCC 9027, Escherichia coli
ATCC 25922, Salmonella abony NCIM 2257,Micrococcus
luteus NCIM 2169 and Salmonella typhimurium histidine
auxotrophs (TA98, TA100, TA102, TA1535 and TA1537).
The reference strains were purchased from ATCC (Amer-
ican Type Culture Collection, Manassas, VA, USA) and
MTCC (Microbial Type Culture Collection and Gene
Bank, Chandigarh, INDIA). Cultures were maintained on
agar plate and stocks were preserved in glycerol (15 % v/v)
and stored at -80 C.
Genetic consistency of B. coagulans MTCC 5856
Test samples
Five production lots of B. coagulans MTCC 5856 (bearing
internal reference number B. coagulans SBC37-01) were
randomly selected for the study i.e. two samples from the
years 2008 (G80241 and G80270) and 2009 (G90236 and
G90467) and one from the year 2010 (G100241). Original
culture was used as reference sample in the study.
Physiological profiling
Samples were subjected to microscopy (Lomo, St. Peters-
burg, Russia) and each sample was grown on glucose yeast
extract agar (GYEA, HiMedia, India). From each sample
three independent colonies were picked and subjected to
biochemical characterization based on sugar fermentation
pattern in basal broth medium as per the standard method
described earlier (Ka¨mpfer et al. 1991). Original culture (B.
coagulans MTCC 5856) was used as reference sample in
the study.
16S rDNA sequencing
Genomic DNA of the B. coagulans MTCC 5856 was
prepared as previously described by Marmur (1961). A
fragment of the 16S rDNA gene was sequenced using an
ABI 3100 automated DNA sequencer as described earlier
(Heyrman and Swings 2001). The sequencing primers used
were 50-GAG TTT GAT CCT GGC TCA-30 (forward pri-
mer, corresponding to positions 9–27 in E. coli numbering)
and 50-ACG GCT ACC TTG TTA CGA CTT-30 (reverse,
1498–1477). The amplified DNA fragment of approxi-
mately 1.5 kb separated on a 1 % agarose gel and purified
by using Qiagen spin columns. The purified fragment was
used directly for DNA sequencing. This sequence was used
in a BLAST search (http://blast.ncbi.nlm.nih.gov/Blast.
cgi).
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GTG 500 and BOX PCR fingerprinting
Two variations of rep-PCR genomic fingerprinting were
performed using the BOX and (GTG)5 primers. Colonies
from B. coagulans MTCC 5856 production batch samples
from three different years (2008, 2009, and 2010) were
isolated. Three separate colonies from each sample were
selected followed by total DNA isolation and then were
subjected to GTG 500 and BOX PCR fingerprinting. BOX
PCR fingerprinting of the five B. coagulans MTCC 5856
production batch samples was performed using repetitive
intergenic DNA sequences (rep-PCR) with the BOX AlR
[50-CTACGGCAAGGCGACGCTGACG-30] primer. Opti-
mal PCR program for the BOX PCR fingerprinting was
used as previously described by Louws et al. (1994).
(GTG)5 fingerprinting of the five B. coagulans MTCC
5856 production batch samples was performed using
repetitive intergenic DNA sequences (rep-PCR) with
(GTG)5 primer (5-GTGGTGGTGGTGGTG-3). The opti-
mal PCR and the amplification cycling conditions for the
rep-PCR were followed as described earlier by Versalovic
et al. (1994). Products were separated by electrophoresis
in 2 % agarose in 19 TBE buffer for 3.5 h at 65 V,
and visualized by staining with ethidium bromide
(0.5 mg mL-1) under ultraviolet light, followed by digital
image capturing using a CCD camera. The reproducibility
of the fingerprint profiles obtained was assessed in at least
three separate experiments. The resulting fingerprints
were analyzed by the BioNumerics V3.0 software pack-
age (Applied Maths, Belgium). Similarities of digitized
profiles were calculated using the Pearson correlation
method and an average linkage (UPGMA) dendrogram
was obtained.
Multi-Locus-Sequence typing (MLST)
Four different samples (three production batches, G80241,
G90236, G90467 and one original culture) of B. coagulans
MTCC 5856 were characterized by the Multilocus
Sequence typing as described by Priest et al. (2004) with
minor modifications (Hoffmaster et al. 2008). Six house-
hold genes were targeted (pta, tpi, glpF, ilvD, ldh, and pur).
Specific primers suitable for B. coagulans were developed
and high fidelity PCR was performed. Amplification
products of the correct size and similar concentrations, as
judged by visual inspection of agarose gels, were obtained
from all the samples and were then purified by using a
QiaAmp PCR purification kit (Qiagen Inc., Valencia, CA)
according to the instructions of the manufacturer. The
purified fragment was used directly for DNA sequencing
with an Applied Biosystems model 3100 automated DNA
sequencing system.
In vitro probiotic evaluation of B. coagulans MTCC
5856
Resistance to gastric acid
The survival of B. coagulans MTCC 5856 spores was
studied by the addition of 1 mL of the suspension into a
series of 9 mL of sterile phosphate-buffered saline (PBS) at
pH 1.5, 3, 4, 5, 6, 7 and 8 (adjusted using 1 N NaOH and
1 N HCl). The incubation temperature was maintained at
37 C and 1 mL sample was taken at 0, 0.5, 1.0, 2.0, 3.0
and 4.0 h. After incubation, serial dilution was done in
sterile saline (0.89 % w/v) and the viable count was enu-
merated by plating on glucose yeast extract agar (HiMe-
dia). Experiments were performed in triplicate at two
different occasions.
Bile tolerance test
Bile tolerance of B. coagulans MTCC 5856 cells was
determined by the method described earlier (Gilliland et al.
1984; Hyronimus et al. 2000). Briefly, overnight grown B.
coagulans MTCC 5856 in MRS broth (20 lL corre-
sponding to 2 9 106 cfu mL-1) was spotted onto MRS
agar plates containing oxgall bile (0.1–1 % w/v) (HiMedia,
Mumbai, India). Plates were incubated at 37 C for 5 days.
The minimal inhibitory concentration (MIC) of bile for
B. coagulans MTCC 5856 was determined as the lowest
concentration totally inhibiting the growth of spots as
judged from visual examination of spots. MRS broth
(HiMedia) was inoculated with approximately 106
cfu mL-1 of B. coagulans MTCC 5856 overnight grown
culture and then supplemented with 0.3 (w/v) and 0.5 %
(w/v) oxgall. Samples were incubated for 24 h at 37 C
with shaking at 120 rpm. Growth in control (no bile) and
test cultures (0.3 and 0.5 % oxgall) was monitored hourly
by measuring absorbance at 600 nm using spectropho-
tometer (Shimadzu Corporation, Kyoto, Japan). In same set
of experiment, the viable count of B. coagulans MTCC
5856 was determined in triplicate on glucose yeast extract
agar (HiMedia) at 0 and 24 h by pour plate method (Ma-
jeed et al. 2016).
Antimicrobial activity against human pathogens
The anti-microbial activity of B. coagulans MTCC 5856
was determined by growing in MRS media. A loopful of
overnight grown culture was added to MRS media and
incubated for 24 h at 37 C with 120 rpm. After 24 h, the
culture was centrifuged (10, 0009g) to remove the cells
and the supernatant was collected, concentrated tenfold by
lyophilization and filter-sterilized through a 0.22 micron
filter (Sartorius, India). The antimicrobial activity was
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performed by a well diffusion assay as previously descri-
bed with minor modifications (Cintas et al. 1995). Briefly, a
5 mL lawn of soft (0.7 % agar) glucose yeast extract
(HiMedia, India), containing 106 cfu mL-1) of the indi-
cator strains (S. aureus ATCC 29213, S. epidermidis ATCC
14990, S. mutans MTCC 1943, P. acnes ATCC 11827, B.
cereus ATCC 14579, P. aeruginosa ATCC 9027, E. coli
ATCC 25922, S. abony NCIM 2257 and M. luteus NCIM
2169) was poured on top of an enriched hard (1.5 % agar)
tryptic soya agar (HiMedia, India). Concentrated super-
natant (50 lL) was added to 6-mm wells punched in the
solidified bi-layer agar. Plates were kept in the refrigerator
(4 ± 2 C) for 5 h to allow the sample to diffuse into the
agar and subsequently incubated at 37 C for 18–20 h.
After incubation, the zone of inhibition was measured and
recorded in mm.
Production of lactic acid
A loopful of an overnight grown culture of B. coagulans
MTCC 5856 was added to glucose yeast extract broth
(HiMedia) and incubated at 37 C for 18 h with 120 rpm.
After incubation, the broth was filtered through 0.22
micron (Sartorius, India) and analyzed for lactic acid
content by using Megazyme kit (K-DLATE 10/04) as per
instructions (Megazyme International Ireland, IDA Busi-
ness Park, Wicklow, Ireland). GYE media was taken as
blank in the assay. The optical rotation of lactic acid pro-
duced by B. coagulans MTCC 5856 was confirmed by
Polarimetric method (Kahya et al. 2001). Above filtered
broth (50 mL) of the overnight grown B. coagulans MTCC
5856 was added to 25 mL Aliquat 336 (50 % w/v in Oleyl
alcohol) (Sigma Chemical Co., St Louis, MO, USA) and
then stirred for 45 min. The mixture was centrifuged at
20009g to separate the aqueous and organic layers. The
organic layer was carefully transferred to a fresh tube.
Similarly, glucose yeast extract broth was taken as blank
control in the experiment. Optical rotation was measured
using Automatic Polarimeter (AUTOPOL I, Rudolph
Research Analytical, Hackettstown, NJ) by taking media
control as the blank. Experiments were performed twice in
triplicate.
In vitro safety evaluation of B. coagulans MTCC
5856
Antibiotic resistance pattern
The minimum inhibitory concentrations (MICs) were
determined as per the guidelines of Clinical and Laboratory
Standards Institute (CLSI 2012). Briefly, the bacterial
suspensions were prepared by suspending 18 h grown
bacterial culture of B. coagulans MTCC 5856 in sterile
normal saline (0.89 % NaCl w/v; HiMedia, Mumbai India).
The turbidity of the bacterial suspension was adjusted to
0.5 McFarland standards (equivalent to 1.5 9 108 colony
forming units (cfu mL-1). Clindamycin, kanamycin,
ampicillin, streptomycin, vancomycin, erythromycin, gen-
tamicin, tetracycline and chloramphenicol were purchased
from Sigma Chemical Co. (St Louis, MO, USA). The
antibiotics stock solutions were prepared as per CLSI
guidelines (CLSI 2012) and two fold serial dilutions were
prepared in Mueller–Hinton broth (MHB, Difco Labora-
tories, Detroit, MI USA). The above mentioned bacterial
suspension was further diluted in the MHB and 100 lL
volume of this diluted inoculum was added to each well of
96-well U bottom microtiter plates (Tarson, Mumbai,
India) resulting in the final inoculum of 5 9 105 cfu mL-1
in the well and the final concentration of antibiotics ranged
from 0.0078 to 4 lg mL-1. The plates were incubated at
37 C for 24 h and were visually observed for the absence
or presence of turbidity. The minimum concentration of the
compound concentration showing no turbidity was recor-
ded as MIC.
Bacterial reverse mutation assay
The mutagenic potential of B. coagulans MTCC 5856 by
measuring the ability to induce reverse mutations at
selected loci of Salmonella typhimurium in the presence
and absence of rat liver S9 was performed as per Organi-
zation for Economic Cooperation and Development
(OECD) guidelines (OECD 1997). Briefly, the tester strains
of S. typhimurium histidine auxotrophs (TA98, TA100,
TA102, TA1535 and TA1537) were received from Moltox
Inc, Boone USA. The B. coagulans MTCC 5856, obtained
at a concentration of 15 9 109 cfu g-1, was mixed with
sterile water not more than 30 min prior to use. Muta-
genicity test was performed at concentrations of 312.5,
625, 1250, 2500, and 5000 lg plate-1, with and without
the S9 mixture. 100 lL of tester strain (S. typhimurium
strains), 50 lL of test article (B. coagulans MTCC 5856)
were added to 2.0 mL of molten selective top agar at
45 ± 2 C. After mixing thoroughly, the mixture was
overlaid onto the surface of 25 mL of minimal glucose
agar. The Petri plates were incubated for 48–72 h at
37 ± 2 C. The plate incorporation methodology followed
in this study was originally described by Ames et al. (1975)
and updated by Maron and Ames (1983). Similarly, sterile
water was used as the negative/vehicle control in the study.
The positive control factors were methyl methane sulpho-
nate (MMS), sodium azide, 9-aminoacridine (9-AA),
Nitrofluorene and 2 aminoanthracene (2-AA). The experi-
ment was performed both with and without an S9
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activation system (AroclorTM 1254-induced rat liver S9).
Experiments were performed in triplicate.
Vero cell cytotoxicity assay
The ability of the B. coagulans MTCC 5856 to produce
enterotoxins was determined by the method described by
From et al. (2005). Briefly, a single isolated colony of B.
coagulans MTCC 5856 and Bacillus cereus ATCC 14579
were added to brain heart infusion broth (HiMedia) sup-
plemented with 1 % glucose and incubated at 32 C for
overnight. The optical density was checked at 600 nm and
normalized to 1.0 for all the samples. 1 mL of this solution
was further inoculated to 100 mL of fresh BHI broth
supplemented with 1 % glucose (w/v) and incubated at
32 C overnight. After incubation, samples were cen-
trifuged at 16,1009g for 50 min and supernatants were
stored at -20 C until testing. Toxicity was determined by
adding 100 lL of supernatant to cause swelling, rounding,
and disseminating of the Vero cell layer. Each well was
examined microscopically after 1, 3, and 5 h of incubation
with 5 % CO2 and 37 C and compared with a positive
control supernatant (from B. cereus ATCC 14579 with the
addition of 3, 10, 30, and 100 lL to four different wells)
(From et al. 2005). After 5 h of incubation, media from the
wells were removed and replaced with 100 lL of fresh
media, 10 lL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) (Sigma) was added. Plates
were further incubated for 3 h at 37 C in a CO2 incubator.
Formation of formazan salt by mitochondrial dehydroge-
nases was determined by an ELISA reader (Fluostar
Optima, BMG LABTECH, Germany) at 565 nm. The
percentage viability was calculated with respect to the
untreated cells.
Detection of enterotoxin genes by PCR
The presence of B. cereus-like enterotoxin genes (hblC,
nheA, nheB, nheC and cytK) in B. coagulans MTCC 5856
were detected by PCR amplification method as previously
described (From et al. 2005). B. cereus ATCC 14579
was used as the positive control in the study. Briefly,
B. coagulans MTCC 5856 and B. cereus ATCC 14579
were grown on sheep blood agar plates for 24 h at 30 C.
A loopful of all the cultures were inoculated into BHI
broth supplemented with 1.0 % glucose and incubated at
30 C for 6 h with shaking (120 rpm). After incubation, the
cells were harvested by centrifugation and pellets were
frozen at –20 C overnight. Total DNA was extracted using
lysozyme enzyme (10 mg mL-1) followed by the addition
of DNAzol reagent (Thermo Fisher Scientific). PCR was
performed by using a Gene Cycler (Bio-Rad). The primers
for all five genes and PCR conditions were used as
described by From et al. (2005). 16S rDNA gene as PCR
positive control and primers without template were taken as
negative control to validate PCR amplification conditions.
Experiments were performed thrice independently at differ-
ent experiments. PCR mixture (5 lL) was analyzed on a
2 % agarose gel.
Stability study of B. coagulans MTCC 5856
Stability of B. coagulans MTCC 5856 in powder form was
studied to determine the shelf life at room temperature.
Two standardized commercial preparations equivalent to
15 9 109 and 6 9 109 cfu g-1 were considered for the
study. The long term stability study of B. coagulans MTCC
5856 was performed at room temperature according to ICH
guidelines Q1A (R2) (ICH 2003). B. coagulans MTCC
5856 samples used in the study were manufactured by
Sami Labs Limited (Bangalore, India) by following pro-
prietary in-house manufacturing process (Majeed et al.
2016). Pure B. coagulans MTCC 5856 spores were spray–
dried and diluted with maltodextrin (Sanwa Starch Co. Ltd.
Kashihara, Nara, Japan) to achieve the desired concentra-
tion of 15 9 109 and 6 9 109 cfu g-1 for the finished
product. Samples (50 g) were sealed inside double trans-
parent polyethylene bags (4 9 4 in.) and then transferred
to HDPE bottles capacity of 100 g which were stored at
controlled temperature and humidity. Long term study was
conducted at 25 ± 2 C and relative humidity (RH)
60 % ± 5 % throughout the respective study period.
Samples were analysed at 0, 3, 6, 9, 12, 18, 24 and
36 months. After every time interval, 1.0 g of B. coagulans
MTCC 5856 sample was thoroughly mixed in sterile saline
and then incubated in water bath for 30 min at 75 C,
followed by immediate cooling to below 45 C. This sus-
pension was further serially diluted in sterile saline and the
viable count was enumerated by plating on glucose yeast
extract agar (HiMedia, Mumbai, India) and then plates
were incubated at 37 C for 48–72 h. Each analysis was
performed twice in triplicate. Average mean of spore
viable counts are expressed in log10 cfu g
-1.
Statistical analysis
The values were calculated as the mean of individual
experiments in triplicate and compared with those of the
control groups. Differences between two mean values were
calculated by Student’s t test. The chosen level of signifi-
cance for all statistical tests was P\ 0.05.
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Results
Genetic consistency of B. coagulans MTCC 5856
Microscopy, colony morphology and physiological
profiling
Samples from production lots of B. coagulans MTCC 5856
contain a mixture of ellipsoidal terminal spores and vege-
tative cells (Fig. 1a). Colonies from B. coagulans MTCC
5856 samples easily were grown on GYE media, yielding
uniform, 1–3 mm in diameter, white to cream, smooth
colonies (Fig. 1b) that contain vegetative rod shaped cells
(Fig. 1b). Five different production lots were compared
with reference sample for acid production from 21 sugars.
The results showed that all colonies isolated from five
different samples had an identical phenotype, consistent
with the phenotype of B. coagulans (Table S1). Bio-
chemical profiling and 16S rDNA confirmed that the strain
present was B. coagulans, and that its identity was con-
sistent over at least a period of 3 years.
GTG 500 and BOX PCR fingerprinting
GTG 500 fingerprinting analysis indicated that the sample
contained one and the same strain over the 3 years period
of production (Fig. 2). BOX-PCR fingerprints of the six B.
coagulans MTCC 5856 samples (five production lots and
one reference samples) were performed using repetitive
intergenic DNA sequences (rep-PCR). Genotype of each
strain could be distinguished according to distribution of
PCR bands in different size. From each sample two inde-
pendent colonies were tested. The isolated colonies from
all five B. coagulans MTCC 5856 production samples had
identical BOX PCR fingerprints (Fig. 3). This was another
confirmation that the strain present was B. coagulans, and
that its identity was consistent over at least 3 years of time.
Multi-Locus-Sequence typing
Multi-Locus-Sequence typing was performed on B. coag-
ulans MTCC 5856 production batch samples targeting six
household genes (pta, tpi, glpF, ilvD, ldh, and pur). Fig-
ure S1 shows the bands generated in the high fidelity PCR.
The obtained sequences were aligned and compared to the
sequences from an unrelated B. coagulans strain (strain
36D1), which was available in the public domain. The
alignment of ilvD was shown as an example in Figure S2
(rest of the alignments are not shown). The alignments
clearly showed that the sequences from the B. coagulans
MTCC 5856 were all identical, but different at various
points from 36D1, confirming the ability of the method to
distinguish different strains from the same species. MLST
study indicated that there was no change in the household
genes, which are far more sensitive to mutation than the
16S rDNA gene. This was yet another confirmation of
strain purity and consistency over a period.
In vitro evaluation of probiotic potential
of B. coagulans MTCC 5856
Resistance to gastric acid
There was no significant difference (4–7 %) in spore count
at pH 3 to pH 8.0 in comparison to the initial spore count
up to 4 h of the study (Fig. 4). However, 0.9 and 2.1 log10
reduction was observed at pH 1.5 in 1 and 4 h respectively.
Results of the study confirmed the stability of B. coagulans
MTCC 5856 spores in acidic as well as alkaline pH
conditions.
Fig. 1 Phase contrast microscopic image (91000 magnification) of B. coagulansMTCC 5856 powder (a), vegetative cells (c) and colony grown
on GYE agar plate (b)
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Bile tolerance test
Bacillus coagulans MTCC 5856 growth was observed on
the agar plate containing bile salt (1 % w/v) which indi-
cated its tolerance against bile salt. Further, bile tolerance
assay was performed by supplementing 0.3 and 0.5 % ox
bile to the MRS broth. There was no significant difference
of B. coagulans MTCC 5856 growth observed in presence
and absence of ox bile (0.3 and 0.5 % w/v; Fig. 5). Simi-
larly, there was no significant difference in the viability of
B. coagulans MTCC 5856 in the presence and absence of
bile salt (data not shown).
Antimicrobial activity against human pathogens
Bacillus coagulans MTCC 5856 showed broad spectrum
antibacterial activity against human pathogens. It exhibited
inhibitory activity against a panel of Gram positive and
Gram negative pathogens including M. luteus NCIM 2169
(Table 1).
Production of lactic acid
Lactic acid production by B. coagulans MTCC 5856 was
estimated by using a Megazyme kit. The total lactic acid
produced by B. coagulans MTCC 5856 was 4.02 g/L. L-
form of lactic acid was 3.99 g/L ([99 %) and D-form of
lactic acid was 0.031 g/L. This was further confirmed by
Polarimetric method and found L-form of lactic acid was
exclusively produced by B. coagulans MTCC 5856.
Fig. 2 Cluster analysis of
digitized banding patterns,
generated by rep-PCR using the
(GTG)5 primer, of B. coagulans
MTCC 5856 isolates. The
dendrogram was constructed
using the unweighted pair-group
method using arithmetic
averages with correlation levels
expressed as percentage values
of the Pearson correlation
coefficient. Arrows indicate the
bands shared by the majority of
the isolates
Fig. 3 BOX-PCR fingerprints of the five B. coagulans MTCC 5856
samples. Two isolates form each sample was taken. Sample 1,
LactoSpore lot G80241, sample 2, G90236/H; sample 3, original
culture; sample 4, G80270, sample 5, G90467; sample 6, G100241
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In vitro safety assessment of B. coagulans MTCC
5856
Antibiotic resistance pattern
The MIC values of antibiotics against B. coagulans MTCC
5856 are given in Table 2. All the tested antibiotics (clin-
damycin, kanamycin, ampicillin, streptomycin, van-
comycin, erythromycin, gentamicin, tetracycline and
chloramphenicol) showed a MIC range of
0.0078–1.0 lg mL-1 against B. coagulans MTCC 5856
indicating its susceptibility against antibiotics, meeting the
requirements of EFSA.
Bacterial reverse mutation assay
The results of mutagenicity test show that B. coagulans

















pH 1.5 pH 3.0 pH 4.0 pH 5.0 pH 6.0 pH 7.0 pH 8.0
Fig. 4 Bacillus coagulans
MTCC 5856 survival at various
pH values (1.5–8.0) in
phosphate-buffered saline. The
values are expressed in log10
spores g-1. Data represent the
mean and standard deviations




















Control without Ox bile
0.3% Ox bile
0.5% Ox bile
Fig. 5 In-vitro effect of ox bile salt on the growth of B. coagulans
MTCC 5856. The overnight grown fresh culture of B. coagulans
MTCC 5856 was inoculated in MRS broth with and without 0.3 % ox
bile salt (w/v) or 0.5 % ox bile salt (w/v). Values are mean (±SD)
from three independent determinations. No significant difference of
B. coagulans MTCC 5856 growth observed in presence and absence
of ox bile (0.3 and 0.5 % w/v) (P[ 0.05)
Table 1 Antimicrobial activity
of B. coagulans MTCC 5856
against tested bacteria
S. no. Tested organisms Zone of inhibition (mm)
1 Staphylococcus aureus ATCC 29213 16.75 ± 1.0
2 Staphylococcus epidermidis ATCC 14990 14.00 ± 1.5
3 Streptococcus mutans MTCC 1943 17.75 ± 2.0
4 Propionibacterium acnes ATCC 11827 16.25 ± 0.6
5 Bacillus cereus ATCC 14579 16.75 ± 1.5
6 Pseudomonas aeruginosa ATCC 9027 18.75 ± 2.1
7 Escherichia coli ATCC 25922 19.50 ± 2.1
8 Salmonella abony NCIM 2257 16.00 ± 1.0
9 Micrococcus luteus NCIM 2169 17.00 ± 1.5
Anti-microbial activity was determined by well diffusion assay as described by Cintas et al. (1995). Data
represent the mean ± SD of three independent experiments performed in triplicate
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revertants in the five Salmonella strains (TA98, TA100,
TA102, TA1535 and TA1537), compared with their neg-
ative controls, either absence or presence of the S9 meta-
bolic activation system. Further, no dose-dependent
mutagenic effects were caused by the B. coagulans MTCC
5856 spores (up to 5000 lg plate-1). B. coagulans MTCC
5856 spores did not show any mutagenic activity under the
experimental conditions.
Vero cell cytotoxicity assay
Bacillus cereus ATCC 14579 was taken as positive control
in the study to compare with B. coagulans MTCC 5856.
Microscopic observation revealed that no swelling,
rounding and disseminating of Vero cells when incubated
with 100 lL of supernatant of the B. coagulans MTCC
5856 for 5 h. However, B. cereus showed swelling,
rounding and disseminating of Vero cells. Further, B.
cereus ATCC 14579 supernatant (100 lL) showed 23 %
reduction in viability of Vero cells when treated for 5 h.
However, B. coagulans MTCC 5856 did not yield any PCR
product, indicating the absence of B. cereus-like entero-
toxin genes (Fig. 6).
Detection of enterotoxin genes by PCR
Bacillus cereus ATCC 14579 was found to be positive for
all five B. cereus enterotoxin genes. However, B. coagulans
MTCC 5856 did not yield any PCR product indicating
absence of B. cereus-like enterotoxin genes (Fig S3).
Stability studies of B. coagulans MTCC 5856
The results of B. coagulans MTCC 5856 stability studies
are expressed in log10 cfu g
-1 (Fig. 7). There were very
negligible reductions in spore counts of B. coagulans
MTCC 5856 in both the samples (15 9 109 and
6 9 109 cfu g-1) compared with the respective initial
counts thus showing the stability of both the preparations
over a period of 36 months (Fig. 7).
Discussion
In this study, a detailed biochemical profiling data indi-
cated that the same strain was present over three consec-
utive years of production. Further, random genomic
technique GTG 500 fingerprinting showed that all B. coag-
ulans MTCC 5856 production batch samples had clustered
together with at least 80 % similarity. This was an indi-
cation that all samples contained one and the same strain
over the 3 years of production. Similarly, BOX PCR
Table 2 Minimum inhibitory concentrations (MICs) of antibiotics
against B. coagulans MTCC 5856
S. no. Antibiotics MIC (lg mL-1)
1 Clindamycin hydrochloride 0.0078
2 Kanamycin sulphate 1.0
3 Ampicillin sodium salt 0.062
4 Streptomycin sulphate 1.0
5 Vancomycin hydrochloride 0.25
6 Erythromycin 0.125
7 Gentamicin sulphate 0.062
8 Tetracycline hydrochloride 0.062
9 Chloramphenicol 1.0
MICs of antibiotics were determined as per CLSI guidelines against






















B. cereus ATCC 14579
* 
**
Fig. 6 Effect of B. coagulans MTCC 5856 and B. cereus ATCC
14579 on the cell viability of Vero cell line. The percentage viability
was calculated with respect to the OD of untreated cells (treated with
brain heart infusion broth). Data represent the mean and standard
deviations (±SD) of three different experiments performed in

















Preparation 1 Preparation 2
Fig. 7 Viability of B. coagulans MTCC 5856 during the storage at
room temperature (25 ± 2 C with RH 60 % ± 5 %). Two stan-
dardized commercial preparations equivalent to 15 9 109 (prepara-
tion 1) and 6 9 109 cfu g-1 (preparation 1) were studied. Average
means of spore viable counts are expressed in log10 cfu g
-1. Each
time point represents the mean log10 standard deviations (±SD) of
three different experiments performed in duplicate
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fingerprints were identical in all B. coagulans MTCC 5856
production samples. Random genomic fingerprinting
techniques such as BOX–PCR fingerprint and GTG 500
fingerprinting have been widely used for molecular typing
of strains due to its good reproducibility, discriminative
power, simple procedure, and low cost (Olive and Bean
1999; Zhu et al. 2006). This is the first detailed study to
report the identity and genetic consistency of a commercial
probiotic strain (B. coagulans MTCC 5856).
Bacillus coagulans is a very heterogeneous species with
a high intra-species genomic diversity (De Clerck et al.
2004). The 16S rRNA sequence is suitable for estimating
relatedness between different isolates, but cannot be used
to discern exactly the different strains of B. coagulans. This
means that strains with a nearly identical 16S rRNA
sequence may have completely different economic, his-
torical and practical traits (De Clerck et al. 2004). MLST
data confirmed that there was no change in the household
genes of B. coagulans MTCC 5856 strain over the period
of 3 years unlike the other commercial probiotic prepara-
tions (Gilliland et al. 1984; Hughes and Hillier 1990;
Canganella et al. 1997; Hamilton-Miller and Shah 2002;
Weese 2002; Aureli et al. 2010). To the best of our
knowledge, for the first time, the current study provides
scientific evidence that the same strain of B. coagulans
MTCC 5856 was present in multiple years of production of
a commercial preparation.
The commercial probiotic strains may alter in different
ways for a variety of purposes. The probiotic strain may
undergo various phenotypic changes during the continuous
and multiple years of commercial production (Sanders
et al. 2014). These changes may alter the expression of
physiological traits owing to the live nature of probiotics.
Hence, genetic or phenotypic changes, by accident or
design, might affect the efficacy or safety of commercial
probiotics (Sanders et al. 2014). Therefore, we evaluated
in vitro probiotic potential, safety and stability of the
commercial probiotic strain (B. coagulans MTCC 5856),
marketed as a dietary ingredient for nearly two decades.
The in vitro study was conducted to mimic the condition of
human gastrointestinal tract by treating the spores at highly
acidic pH and growing B. coagulans MTCC 5856 at high
bile salt concentration. B. coagulans MTCC 5856 showed
resistance to highly acidic pH and high bile concentration.
Probiotic organisms are reported to produce anti-microbial
agents which inhibit the growth of pathogenic bacteria.
Supernatant of B. coagulans MTCC 5856 exerted broad
spectrum of anti-microbial activity by inhibiting not only
the growth of Gram positive but Gram negative pathogens
also. Lactic acid bacteria are known to produce two
stereoisomers of lactic acid, namely, D and L lactic acid.
L–lactic acid can be readily metabolized by human whereas
the D-isomer cannot be metabolized and is considered to be
a causative agent for acidosis (Coronado et al. 1995). The
production of lactic acid by the B. coagulans MTCC 5856
was found to be L (?) lactic acid ([99 %) which was
confirmed by Polarimetric method. This adds up to another
property of B. coagulans MTCC 5856 for the safe use as
probiotic product unlike recently reported complication by
other probiotic products associated with D-lactic acid pro-
duction (Munakata et al. 2010).
Bacillus coagulans MTCC 5856 was found to be sus-
ceptible to all the antibiotics recommended by European
Food Safety Authority. The literature suggested that some
antibiotic resistance genes can be transferred by probiotics
such as Lactobacillus reuteri and E. faecium to the
endogenous flora or to pathogens which may pose a health
risk to human (Marteau 2001; EFSA 2012). Another safety
concern associated with spore forming Bacillus species is
the production of enterotoxins. B. coagulans MTCC 5856
did not cause any physiological or structural changes in
Vero cell and had no significant cytotoxicity in MTT assay.
Additionally, B. coagulans MTCC 5856 was found to be
negative for B. cereus-like enterotoxin genes. Further, B.
coagulans MTCC 5856 did not show any mutagenic effect
in Ames test. The extensive in vitro safety studies revealed
that B. coagulans MTCC 5856 is safe to use and thus
eminently qualifies as a probiotic strain. It is essential to
evaluate proper stability studies to identify probiotic con-
tents and ensure that the organisms claimed on the label are
actually present at the time the probiotic reaches a con-
sumer. B. coagulansMTCC 5856 was found to be stable up
to 36 months at ambient temperature confirming its shelf
life for 3 years unlike the other probiotic products report-
edly not having viable count matching the label claim
(Canganella et al. 1997; Hamilton-Miller and Shah 2002;
Weese 2002; Weese and Martin 2011). Majeed et al.
(2016) reported that B. coagulans MTCC 5856 found to be
stable during processing and respective storage conditions
of baked food, beverages, vegetable oil, and concentrated
glucose syrup and even in brewed coffee.
Conclusions
In conclusion, B. coagulans MTCC 5856 (LactoSpore) is
a commercial probiotic preparation which contains B.
coagulans as the active ingredient and the same strain was
present over multiple years of production. The data pre-
sented in the current study suggests that the B. coagulans
MTCC 5856 did not alter either genetically or phenotypi-
cally and was found to be consistent over multiple years of
commercial production.
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